Search results for "therapy [Encephalitis]"

showing 10 items of 2838 documents

Acute effects of different foam rolling volumes in the interset rest period on maximum repetition performance

2017

Background - Foam rolling (FR) is a ubiquitous intervention utilised for the purpose of acutely increasing the range of motion without subsequent decreases in performance. Thus, it is commonly used during the periworkout period—that is, prior to, during, or after an athlete's workout.\ud \ud Objective - This study investigated how different FR durations applied to the quadriceps during the interset rest periods affects the numbers of repetitions in the knee extension exercise.\ud \ud Methods - Twenty-five females completed four sets of knee extensions with 10 repetitions of maximum load to concentric failure on four occasions. Between each set, a 4-minute rest interval was implemented in wh…

Acute effectsmedicine.medical_specialtyB100Physical Therapy Sports Therapy and RehabilitationmassageConcentric03 medical and health sciencesself-myofascial release0302 clinical medicineRest (finance)Medicine030222 orthopedicsRepetition (rhetorical device)business.industrylcsh:RM1-950030229 sport sciencesConfidence intervalself-manual therapyRest periodlcsh:Therapeutics. PharmacologyPhysical therapyfatigueFoam rollingbusinessRange of motionResearch Paper
researchProduct

Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemothe…

2010

Purpose We analyzed the incidence, risk factors, and outcome of therapy-related myeloid neoplasms (t-MNs) in patients with acute promyelocytic leukemia (APL) in first complete remission (CR). Patients and Methods From 1996 to 2008, 1,025 patients with APL were enrolled onto three sequential trials (LPA96, LPA99, and LPA2005) of the Programa Español para el Tratamiento de Enfermedades Hematológicas and received induction and consolidation therapy with all-trans-retinoic acid (ATRA) and anthracycline-based chemotherapy. Results Seventeen of 918 patients who achieved CR developed t-MN (10 with < 20% and seven with ≥ 20% of bone marrow blasts) after a median of 43 months from CR. Partial and…

Acute promyelocytic leukemiaAdultMaleCancer Researchmedicine.medical_specialtyMyeloidAnthracyclinemedicine.medical_treatmentTretinoinGastroenterologyLeukemia Promyelocytic AcuteTretinoinRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansCumulative incidenceAnthracyclinesProspective StudiesAgedChemotherapybusiness.industryIncidenceNeoplasms Second PrimaryMiddle Agedmedicine.diseasePrognosisSurgeryLeukemiamedicine.anatomical_structureTreatment OutcomeOncologyFemaleBone marrowbusinessBone Marrow Neoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic…

2017

Recently, studies in adults with acute promyelocytic leukemia (APL) showed high cure rates in low-risk patients treated with all-trans retinoid acid (ATRA) and arsenic trioxide (ATO), while toxicities were significantly reduced compared to the standard treatment with ATRA and chemotherapy. Here we report about first experience with 11 pediatric patients with low-risk APL treated with ATRA and ATO. All patients stayed in molecular remission. All suffered from hyperleukocytosis. Two patients experienced reversible severe side effects. One suffered from osteonecroses at both femurs, seizures, as well as posterior reversible encephalopathy syndrome, the other patient had an abducens paresis.

Acute promyelocytic leukemiaMalemedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentMedizinTretinoinGastroenterologyArsenicals03 medical and health scienceschemistry.chemical_compound0302 clinical medicineArsenic TrioxideLeukemia Promyelocytic AcuteTretinoinInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansRetinoidArsenic trioxideChildneoplasmsParesisRetrospective StudiesChemotherapybusiness.industryStandard treatmentInfantPosterior reversible encephalopathy syndromeOxidesHematologymedicine.diseaseSurgeryTreatment OutcomeOncologychemistry030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemalemedicine.symptombusiness030215 immunologymedicine.drug
researchProduct

Influence of Guideline Operationalization on Youth Activity Prevalence in the International Children's Accelerometry Database

2022

Introduction: The United Kingdom and World Health Organization recently changed their youth physical activity (PA) guidelines from 60 minutes of moderate-vigorous PA (MVPA) every day, to an average of 60 minutes of MVPA per day, over a week. The changes are based on expert opinion due to insufficient evidence comparing health outcomes associated with different guideline definitions. Further, inconsistent guideline operationalization impairs understanding of physical inactivity prevalence. This study used the International Children’s Accelerometry Database to compare approaches to calculating PA compliance among youth and associations with health indicators. Methods: Cross-sectional accelero…

Adolescent/dk/atira/pure/core/keywords/exercise_nutrition_and_health_sciencesPhysical Therapy Sports Therapy and Rehabilitation610 Medicine & health10060 Epidemiology Biostatistics and Prevention Institute (EBPI)VDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850ICADCross-Sectional Studies2732 Orthopedics and Sports MedicineACCELEROMETERAccelerometryCOMPLIANCEPrevalenceVIGOROUS-INTENSITY PHYSICAL ACTIVITYHumansOrthopedics and Sports MedicinePHYSICAL ACTIVITYSPS Exercise Nutrition and Health SciencesSedentary Behavior3612 Physical Therapy Sports Therapy and RehabilitationChildExercise
researchProduct

Participation in organized sports is associated with decreased likelihood of unhealthy lifestyle habits in adolescents

2018

Adolescence is a pivotal time for investing in both present and future health. Thus, it is important to identify arenas for promoting positive adolescent health behaviors and preventing negative ones. The aim of this study was to investigate the associations between organized sports participation (OSP) and a broad range of lifestyle habits in Norwegian adolescents. A comprehensive survey was completed by 13 269 junior high and high school students in southern Norway. Multivariable binary logistic regression models, adjusted for gender, age, and parental education, were used to investigate the associations between OSP and adolescent substance use, dietary habits, physical activity level, pas…

AdolescentCross-sectional studyHealth Behavior030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationNorwegianLogistic regressionOdds03 medical and health sciencesScreen time0302 clinical medicineSurveys and QuestionnairesHumansOrthopedics and Sports MedicineHealthy Lifestyle030212 general & internal medicineExerciseNorwayOdds ratiolanguage.human_languagePhysical activity levelDietlanguagePsychologySportsDemographyAdolescent healthScandinavian Journal of Medicine & Science in Sports
researchProduct

Transition from Youth categories to Elite cycling: relationships between early career performance and UCI World Tour success

2021

BACKGROUND The present study aimed to describe the possible roles of cyclists' early career performance, on the transition process to elite cycling categories. METHODS Data from national and international databases, and results achieved during the UCI World Championships, were retrospectively analysed considering the Italian national Youth-U16, Junior-U18, and U23 categories, and international Junior-U18 and UCI World-Tour categories. RESULTS The 15% of Youth-U16, the 38.8% of Junior-U18 and the 60% of U23 athletes who ranked top-10 between 2007 and 2013, scored points in UCI World Tour competitions between 2012 and 2018. The 1.6% of Youth-U16, the 8.3% of Junior-U18 and 25% of U23 athletes…

AdolescentbiologyAthletesPhysical Therapy Sports Therapy and RehabilitationAthletic PerformanceAchievementbiology.organism_classificationBicyclingAthletesEliteWorld championshipHumansOrthopedics and Sports MedicineEarly careerLow correlationCyclingPsychologyRetrospective StudiesDemographyThe Journal of Sports Medicine and Physical Fitness
researchProduct

Impact of granulocyte colony-stimulating factor (G-CSF) and epoetin (EPO) on hematologic toxicities and quality of life in patients during adjuvant c…

2020

Hematologic toxicities are one of the greatest challenges in adjuvant chemotherapy for breast cancer. This analysis of the ADEBAR trial aims to evaluate application and effect of granulocyte colony-stimulating factor (G-CSF) and epoetin alfa (EPO) on hematologic parameters and fatigue in patients with breast cancer during chemotherapy.In the ADEBAR trial, 1493 patients with node-positive primary breast cancer were randomized to either 6 × 5-fluorouracil, epirubicin, and cyclophosphamide (FEC120) or 4 × epirubicin and cyclophosphamide followed by 4 × docetaxel (EC-DOC). Co-medication with G-CSF or EPO was applied to treat chemotherapy-induced leukopenia or anemia. Fatigue was assessed at bas…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAdolescentCyclophosphamidemedicine.medical_treatmentBreast NeoplasmsSeverity of Illness IndexHemoglobinsLeukocyte CountYoung Adult03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansProspective StudiesFatigueAgedNeoplasm StagingChemotherapyLeukopeniabusiness.industryEpoetin alfaAnemiaLeukopeniaMiddle Agedmedicine.diseaseGranulocyte colony-stimulating factorEpoetin Alfa030104 developmental biologyOncologyDocetaxelChemotherapy Adjuvant030220 oncology & carcinogenesisQuality of LifeFemalemedicine.symptombusinessmedicine.drugEpirubicin
researchProduct

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Ta…

2016

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sen…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalEstronemedicine.drug_classBreast NeoplasmsEstrone03 medical and health scienceschemistry.chemical_compoundFollicle-stimulating hormone0302 clinical medicineBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGynecologyTriptorelin PamoateEstradiolbusiness.industryOvaryEstrogensORIGINAL REPORTSLuteinizing Hormonemedicine.diseaseTriptorelinAndrostadienesTamoxifen030104 developmental biologyOncologychemistryChemotherapy AdjuvantEstrogen030220 oncology & carcinogenesisFemaleFollicle Stimulating HormonebusinessTamoxifenmedicine.drugBlood samplingJournal of Clinical Oncology
researchProduct

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Canc…

2018

AbstractPurpose: This single-arm, open-label phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally advanced or metastatic HER2-negative, hormone receptor (HR)-positive breast cancer.Patients and Methods: Patients received 6-mg oral taselisib capsules daily plus intramuscular fulvestrant (500 mg) until disease progression or unacceptable toxicity. Tumor tissue (if available) was centrally evaluated for PIK3CA mutations. Adverse events (AE) were recorded using NCI-CTCAE v4.0. Tumor response was investigator-determined using RECIST v1.1.Results: Median treatment duration was 4.6 (range: 0.9–40.5) months. All patients expe…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsClass I Phosphatidylinositol 3-KinasesReceptor ErbB-2Phases of clinical researchBreast NeoplasmsDisease-Free SurvivalArticle03 medical and health sciences0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAdverse effectFulvestrantAgedAged 80 and overResponse rate (survey)Fulvestrantbusiness.industryImidazolesCancerMiddle Agedmedicine.diseaseOxazepines030104 developmental biologyReceptors EstrogenOncologyHormone receptor030220 oncology & carcinogenesisMutationToxicityFemalebusinessmedicine.drugClinical Cancer Research
researchProduct

Outcomes of single versus double hormone receptor–positive breast cancer. A GEICAM/9906 sub-study

2018

Abstract Background Retrospective data suggest better outcomes for patients with double hormonal receptor (oestrogen [ER] and progesterone receptor [PgR])–positive (dHR+) early breast cancer, compared with single hormonal receptor–positive, sHR+, (ER+/PgR– or ER–/PgR+) disease. Here, we evaluate the classification according to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ in HER2-negative breast cancer patients enrolled in GEICAM/9906 study ( NCT00129922 ). Methods Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 gene expression assay. Disease-free survival (DFS) and overall surv…

Adult0301 basic medicineOncologyendocrine systemCancer Researchmedicine.medical_specialtyPaclitaxelBreast NeoplasmsDisease-Free Survival03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsProgesterone receptormedicineHumansPAM50Single receptor positiveskin and connective tissue diseasesReceptorCyclophosphamideAgedEpirubicinProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesHormone receptor positivebusiness.industryIncidence (epidemiology)Hazard ratioLuminal aMiddle Agedmedicine.disease030104 developmental biologyClinical Trials Phase III as TopicReceptors EstrogenOncologyIntrinsic subtypesHormone receptor030220 oncology & carcinogenesisFemaleFluorouracilReceptors ProgesteroneTranscriptomebusinesshormones hormone substitutes and hormone antagonistsHormoneEuropean Journal of Cancer
researchProduct